Human adipose-derived stem cells attenuate inflammatory bowel disease in IL-10 knockout mice

Tissue and Cell

Volumn 47, Issue 1, 2015, Pages 86-93

  Jung, Woo Yeun ^a   Kang, Joo Hwan ^a   Kim, Kyung Gon ^a   Kim, Hee Snn ^a   Jang, Byung Ik ^a   Park, Yong Hoon ^a   Song, In Hwan ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Adipose tissue; Inflammatory bowel disease; Interleukin 10; Knockout mice; Mesenchymal stem cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; PIROXICAM; RANTES; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; TLR9 PROTEIN, HUMAN;

ADIPOSE DERIVED STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; INFLAMMATORY BOWEL DISEASE; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; ADIPOCYTE; ANIMAL; BIOLOGICAL THERAPY; BIOSYNTHESIS; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; KNOCKOUT MOUSE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PATHOLOGY; TRANSPLANTATION;

MURINAE; MUS;

ADIPOCYTES; ANIMALS; CELL- AND TISSUE-BASED THERAPY; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; PIROXICAM; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924010379     PISSN: 00408166     EISSN: 15323072     Source Type: Journal    
DOI: 10.1016/j.tice.2014.12.001     Document Type: Article

References (31)

1. Ardizzone S., Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005, 65:2253-2286.
2. Burlacu A., Grigorescu G., Rosca A.M., Preda M.B., Simionescu M. Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. Stem Cells Dev. 2012, 22:643-653.
3. Dharmani P., Chadee K. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key. Curr. Mol. Pharmacol. 2008, 1:195-212.
4. Duijvestein M., Vos A.C., Roelofs H., Wildenberg M.E., Wendrich B.B., Verspaget H.W., Kooy-Winkelaar E.M., Koning F., Zwaginga J.J., Fidder H.H., Verhaar A.P., Fibbe W.E., van den Brink G.R., Hommes D.W. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59:1662-1669.
5. Galle J., Bader A., Hepp P., Grill W., Fuchs B., Kas J.A., Krinner A., Marquass B., Muller K., Schiller J., Schulz R.M., von Buttlar M., von der Burg E., Zscharnack M., Loffler M. Mesenchymal stem cells in cartilage repair: state of the art and methods to monitor cell growth, differentiation and cartilage regeneration. Curr. Med. Chem. 2010, 17:2274-2291.
6. Garrett W.S., Gordon J.I., Glimcher L.H. Homeostasis and inflammation in the intestine. Cell 2010, 140:859-870.
7. Grisham M.B. Do different animal models of IBD serve different purposes?. Inflamm. Bowel Dis. 2008, 2(Suppl. 14):S132-S133.
8. Hasnain S.Z., Tauro S., Das I., Tong H., Chen A.C., Jeffery P.L., McDonald V., Florin T.H., McGuckin M.A. IL-10 promotes production of intestinal mucus by suppressing protein misfolding and endoplasmic reticulum stress in goblet cells. Gastroenterology 2013, 144:357-368.
9. Hyams J., Damaraju L., Blank M., Johanns J., Guzzo C., Winter H.S., Kugathasan S., Cohen S., Markowitz J., Escher J.C., Veereman-Wauters G., Crandall W., Baldassano R., Griffiths A., Group T.S. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 2012, 10:391-399.
10. Javazon E.H., Beggs K.J., Flake A.W. Mesenchymal stem cells: paradoxes of passaging. Exp. Hematol. 2004, 32:414-425.
11. Juillerat P., Pittet V., Vader J.P., Burnand B., Gonvers J.J., de Saussure P., Mottet C., Seibold F., Rogler G., Sagmeister M., Felley C., Michetti P., Froehlich F., Swiss I.B.D.C.S.G. Infliximab for Crohn's disease in the Swiss IBD cohort study: clinical management and appropriateness. Eur. J. Gastroenterol. Hepatol. 2010, 22:1352-1357.
12. Liu Y., Wang L., Kikuiri T., Akiyama K., Chen C., Xu X., Yang R., Chen W., Wang S., Shi S. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat. Med. 2011, 17:1594-1601.
13. MacDonald T.T., Monteleone I., Fantini M.C., Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011, 140:1768-1775.
14. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16:1215.
15. Monteleone G., Fina D., Caruso R., Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr. Opin. Gastroenterol. 2006, 22:361-364.
16. Neuman M.G. Immune dysfunction in inflammatory bowel disease. Transl. Res.: J. Lab. Clin. Med. 2007, 149:173-186.
17. Neurath M.F. Animal models of inflammatory bowel diseases: illuminating the pathogenesis of colitis, ileitis and cancer. Dig. Dis. 2012, 30(Suppl. 1):S91-S94.
18. Owczarek D., Cibor D., Szczepanek M., Mach T. Biological therapy of inflammatory bowel disease. Pol. Arch. Med. Wewn. 2009, 119:84-88.
19. Rachmilewitz D. How have animal models of IBD contributed to advance IBD therapy?. Inflamm. Bowel Dis. 2008, 2(14 Suppl.):S134-S135.
20. Rath H.C., Herfarth H.H., Ikeda J.S., Grenther W.B., Hamm T.E., Balish E., Taurog J.D., Hammer R.E., Wilson K.H., Sartor R.B. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J. Clin. Investig. 1996, 98:945-953.
21. Schmidt C., Marth T., Wittig B.M., Hombach A., Abken H., Stallmach A. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology 2002, 70:177-183.
22. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N., Carosella E.D., Deschaseaux F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
23. Singh U.P., Singh N.P., Singh B., Mishra M.K., Nagarkatti M., Nagarkatti P.S., Singh S.R. Stem cells as potential therapeutic targets for inflammatory bowel disease. Frontiers Biosci. 2010, 2:993-1008.
24. Singh U.P., Singh S., Singh R., Cong Y., Taub D.D., Lillard J.W. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J. Interf. Cytokine Res. 2008, 28:31-43.
25. Song I.H. Adult mesenchymal stem cells for cell therapy in clinical application. Yeungnam Univ. J. Med. 2009, 26:1-14.
26. Stadnicki A., Colman R.W. Experimental models of inflammatory bowel disease. Arch. Immunol. Ther. Exp. 2003, 51:149-155.
27. Uccelli A., Benvenuto F., Laroni A., Giunti D. Neuroprotective features of mesenchymal stem cells. Best Pract. Res. Clin. Haematol. 2011, 24:59-64.
28. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Investig. 2006, 116:1310-1316.
29. Yin T., Li L. The stem cell niches in bone. J. Clin. Investig. 2006, 116:1195-1201.
30. Zhang Z., Liu J., Liu Y., Li Z., Gao W.Q., He Z. Generation, characterization and potential therapeutic applications of mature and functional hepatocytes from stem cells. J. Cell. Physiol. 2012, 228:298-305.
31. Zhao S., Wehner R., Bornhauser M., Wassmuth R., Bachmann M., Schmitz M. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev. 2010, 19:607-614.